MDxHealth (FRA:O6C1) FFO


FRA:O6C1 MDxHealth SA FRA:O6C1
33 GF Score
Price €0.12
GF Value €0.54
Valuation Possible Value Trap
! 5 Warning Signs
View Full Analysis

What is MDxHealth FFO?

FFO (Funds from operations) only applies to REITs.

FRA:O6C1
33GF Score
MDxHealth SA FRA:O6C1
FFO is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is MDxHealth (FRA:O6C1) Overvalued in 2026?

Based on GuruFocus' analysis, MDxHealth stock appears to be undervalued. The current stock price of €0.12 is trading 78.1% below its estimated GF Value™ of €0.54. GuruFocus considers MDxHealth to be Possible Value Trap.

Key valuation signals for FRA:O6C1:

  • FFO:
  • GF Value™: €0.54 vs. price of €0.12 (78.1% below fair value)
  • GF Score™: 33/100 with 5 warning signs

No single metric tells the full story. See the FRA:O6C1 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

MDxHealth Business Description

Other Exchanges MDXH:USA
Address Zone Industrielle des Hauts-Sarts, Rue d’Abhooz, 31, Cap Business Center, Herstal, Liege, BEL, 4040
MDxHealth SA is a multinational healthcare company that provides actionable molecular diagnostic information to personalize the diagnosis and treatment of cancer. Its tests are based on proprietary genomic, epigenetic, and other molecular technologies and assist physicians with the diagnosis of urologic cancers, the prognosis of recurrence risk, and the prediction of response to a specific therapy. It derives revenues from clinical laboratory service testing or the out-licensing of the company's patented DNA methylation platform and biomarkers. Geographically, it derives revenue from the United States of America (USA) and Europe.
33GF Score

Get the complete analysis for FRA:O6C1

FFO is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€0.12
Price
€0.54
GF Value